The incidence and factors associated with the recurrence of supraventricular tachycardia in children: 15 years experience from middle-income country

Limited data are available concerning supraventricular tachycardia (SVT) recurrence. Hence, this study aimed to determine the incidence, outcome, and factors associated with SVT recurrence. This retrospective, observational, population-based study was conducted among children with SVT from 2006 to 2...

Full description

Saved in:
Bibliographic Details
Main Authors: Bah, Mohd Nizam Mat, Zahari, Norazah, Boparam, Baljit Kaur, Sapian, Mohd Hanafi
Format: Article
Published: Springer 2024
Subjects:
Online Access:http://eprints.um.edu.my/44832/
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Malaya
Description
Summary:Limited data are available concerning supraventricular tachycardia (SVT) recurrence. Hence, this study aimed to determine the incidence, outcome, and factors associated with SVT recurrence. This retrospective, observational, population-based study was conducted among children with SVT from 2006 to 2020. The primary outcome measure was SVT recurrence. Kaplan Meier analysis was used to estimate SVT-free at 1, 5, and 10 years after diagnosis. Cox regression analysis was used to identify independent factors associated with recurrence. There were 156 patients with SVT with a median age at diagnosis of 1.9 years (Interquartile range IQR 11 days to 8.7 years) and follow-up for a median of 3.5 years (IQR 1.7 to 6.1 years). 35 patients (22%) had recurrent SVT at a median age of 7.8 years (IQR 4.4 to 12 years). Infants with Wolff-Parkinson-White Syndrome (WPW) had the highest recurrence (11/16, 68%), with 33% SVT-free at 5 years follow-up. The lowest recurrence rate was observed in neonatal diagnosis (2/54, 3.7%) with 98% SVT-free at 5 years follow-up. The independent factors associated with the recurrence of SVT were the diagnosis of WPW with an adjusted hazard ratio (aHR) of 5.2 (95% CI 2.4–11.2), age of more than 1 year at diagnosis (aHR 3.7 95% CI 1.4–9.7), and combine with or need second-line therapy (aHR 4.0 95% CI 1.5–10.7). One in five children with SVT experienced a recurrence, which is more likely for those with WPW, multiple maintenance therapy, and older age at first presentation. Whereas neonates with non-WPW may benefit from shorter maintenance therapy. © 2024, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.